Article Sidebar
Published:
Feb 12, 2013DOI:
10.4314/jpb.v9i1.2Keywords:
Article Details
Copyright of articles published shall reside exclusively with the Faculty of Pharmaceutical Sciences, University of Jos.
DECLARATION & COPYRIGHT TRANSFER
I/We the undersigned author(s) of article entitled
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
Declare as follows:
- The manuscript submitted to Journal of Pharmacy & Bioresources is original and has not been and will be published, whole or in part, in print or electronic format, in any other journal. It is also not being currently considered for publication in any journal.
- The submitted manuscript is a joint decision of all the coauthors.
- Each author has participated sufficiently in the work to warrant his or her inclusion in the list of authors. To this end, each author takes responsibility for appropriate portions of the manuscript.
- Authors have obtained necessary approval to carry out the experiments on animals and human subjects. Approval certificates will be furnished, if required by publishers or editors of the journal.
- Authors do not have any conflict of interest (financial or otherwise) other than those declared.
- If the manuscript is accepted for publication, the authors transfer and assign copyright of the article referenced above to Journal of Pharmacy and Bioresources.
Name & Signature of authors
1. 2.
- 4.
- 6.
- 8.
Corresponding authors name address, affiliation and email:
Main Article Content
Anticonvulsant screening of three N-(2,6-dimethylphenyl)- substituted-benzamides
Abstract
The N-(substituted)-4-aminobenzamides have provided several anticonvulsants that have been extensively investigated. In these series, Ameltolide®, 4-amino-N-(2,6-dimethylphenyl) benzamide (LY201116) is the most potent analogue studied to date. This drug is inactivated in vivo by metabolic N-acetylation, resulting in 4-(acetylamino)-N-(2,6-dimethylphenyl)benzamide. Efforts to limit this metabolic inactivation led to the synthesis of two analogues: 3,4-diamino-N-(2,6-dimethylphenyl) benzamide and N-(2,6-dimethylphenyl) benzamide. The anticonvulsant activities of these two compounds were determined against their ability to inhibit pentylenetetrazole induced seizure in rats after oral administration at three dose levels, i.e. 10mg/Kg, 30mg/Kg, and 100mg/Kg at 30
minutes interval. In addition, the effect of time of oral administration at 30mg/Kg dose level was determined at time intervals of 1h, 2h, and 4h respectively for 3,4-diamino-N-(2,6-dimethylphenyl)benzamide. Our results were compared with that of ameltolide® and carbamazepine.
Keywords: Anticonvulsant, Benzamide, Epilepsy and Seizures
